KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Short term Debt (2016 - 2025)

Merck (MRK) has disclosed Short term Debt for 17 consecutive years, with $2.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Short term Debt fell 2.27% to $2.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 billion, a 2.27% decrease, with the full-year FY2025 number at $2.6 billion, down 2.27% from a year prior.
  • Short term Debt was $2.6 billion for Q4 2025 at Merck, up from $1.4 billion in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $7.3 billion in Q1 2021 to a low of $887.0 million in Q3 2023.
  • A 5-year average of $2.5 billion and a median of $2.5 billion in 2021 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: tumbled 83.34% in 2022, then skyrocketed 255.02% in 2024.
  • Merck's Short term Debt stood at $2.4 billion in 2021, then decreased by 19.32% to $1.9 billion in 2022, then fell by 29.5% to $1.4 billion in 2023, then soared by 93.08% to $2.6 billion in 2024, then dropped by 2.27% to $2.6 billion in 2025.
  • Per Business Quant, the three most recent readings for MRK's Short term Debt are $2.6 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.4 billion (Q2 2025).